The Company approved the 2013 Equity Incentive Plan in October 2013, which was amended in June 2016 and June 2018, (Amended 2013 Plan). The Amended 2013 Plan provided for the granting of stock options, restricted stock units (RSU), stock appreciation rights, and stock units to certain employees, members of the board of directors and consultants of the Company.

In May 2023, the Company's Board of Directors approved the 2023 Equity Incentive Plan (2023 Equity Plan) to replace the Amended 2013 Plan. On June 30, 2023, the Company's stockholders approved the 2023 Equity Plan at the Company's 2023 annual meeting of stockholders. Pursuant to the 2023 Equity Plan, the Company will not make any further grants under the Amended 2013 Plan following June 30, 2023, though awards previously granted under the Amended 2013 Plan will remain outstanding. The 2023 Equity Plan is effective for a period of ten years after June 30, 2023, and a total of 5,450,000 shares of the Company’s common stock, in addition to shares of the Company’s common stock that are subject to awards granted under the Amended 2013 Plan that are outstanding as of such date and that are subsequently forfeited, cancelled, or expire before being exercised or settled in full, are authorized for issuance under the 2023 Equity Plan. As of March 31, 2024, there were 3,692,753 shares of common stock available for grant under the 2023 Equity Plan.

In 2022 the Company granted cash awards under its Management Cash Incentive Plan, as amended (the Management Cash Incentive Plan). The Management Cash Incentive Plan provides its participants with the opportunity to earn cash incentive awards for the achievement of goals relating to the performance of the Company and was adopted in 2016. The cash awards vest in four annual installments from the date of grant based on continued service and entitle the employees to receive a cash payment, on the earlier of (i) four years from the date of grant or (ii) a change of control, equal in value to the amount by which the then value of the Company’s common stock exceeds the base value. As of March 31, 2024, $0.1 million was accrued as compensation expense for vested cash awards. There was no unrecognized expense as of March 31, 2024.

In 2022, the Company granted performance cash settled bonus awards (CSBUs) under its Management Cash Incentive Plan. As a result of the acceptance by the FDA of the Company's submission of an NDA for reproxalap (Performance Criteria), the awards will vest in four annual installments from the date of grant based on continued service, and entitle the employees to receive a cash payment for each vested CSBU, on the earlier of (i) four years from the date of grant or (ii) a change of control, equal in value of the closing price per share of the Company's common stock on the Nasdaq Capital Market on the payment date. As of March 31, 2024, $1.6 million was accrued as compensation expense for CSBUs as the Performance Criteria was met in February 2023. There was no unrecognized expense as of March 31, 2024.

The Company recognizes stock-based compensation expense over the requisite service period. The Company's share-based awards are accounted for as equity instruments, except for cash awards and CSBUs, which are accounted for as liabilities. The amounts included in the consolidated statements of operations relating to stock-based compensation associated with the two equity incentive plans, cash awards, and CSBUs are as follows:


	Three Months Ended March 31,
	2024		2023
Research and development expenses	$	864,184	$	2,191,368
General and administrative expenses	$	684,653	$	1,998,988
Total stock-based compensation expense	$	1,548,837	$	4,190,356

The table below summarizes activity relating to stock options under the incentive plans for the three months ended March 31, 2024:


	Number of Shares			Weighted Average Exercise Price		Weighted Average Contractual Term (Years)		Aggregate Intrinsic Value(a)
Outstanding at December 31, 2023		5,868,816		$	6.40		6.44	$	3,996
Granted		2,101,648			3.62				—
Expired		(55,165	)		7.68				—
Forfeited		(31,506	)		4.49				—
Outstanding at March 31, 2024		7,883,793		$	5.66		7.23	$	—
Exercisable at March 31, 2024		4,522,334		$	6.31		5.66	$	—

(a)

The aggregate intrinsic value in this table was calculated on the positive difference, if any, between the closing price per share of the Company’s common stock on March 31, 2024 of $3.27 and the per share exercise price of the underlying options.

As of March 31, 2024, unamortized stock-based compensation for stock options outstanding was $10.8 million and is expected to be recognized over a weighted average period of 2.93 years. Total unrecognized compensation cost will be adjusted for future forfeitures, if necessary.

The table below summarizes activity relating to restricted stock units (RSUs) for the three months ended March 31, 2024:


	Number of Shares			Weighted-Average Grant Date Fair Value
Outstanding at December 31, 2023		944,497		$	5.30
Exercised/Released		(212,441	)		5.33
Outstanding at March 31, 2024		732,056		$	5.29

There were no RSUs granted during the three months ended March 31, 2024. The total grant date fair value of RSUs vested was $1.1 million for the three months ended March 31, 2024. As of March 31, 2024, the outstanding RSUs had unamortized stock-based compensation of $3.2 million with a weighted-average remaining recognition period of 2.29 years and an aggregate intrinsic value of $2.4 million.

At March 31, 2024, the Company had 2,928,226 shares available for issuance under the 2016 Employee Stock Purchase Plan (2016 ESPP). A summary of the weighted-average grant-date fair value, and total stock-based compensation expense recognized related to the 2016 ESPP are as follows:


	Three Months Ended March 31,
	2024		2023
Weighted-average grant-date fair value per share	$	1.44	$	2.70
Total stock-based compensation expense	$	5,099	$	17,040